You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Increased incidence of GERD in GLP-1 treated patients: fact or artefact?
  1. Daniel Robert Quast1,
  2. Juris J Meier2
  1. 1 Diabetes, Endocrinology and Metabolism Section, Department of Internal Medicine I, Katholisches Klinikum Bochum Sankt Josef-Hospital, Bochum, Germany
  2. 2 Department of Internal Medicine, Gastroenterology and Diabetes, Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
  1. Correspondence to Dr Juris J Meier, Department of Internal Medicine, Gastroenterology and Diabetes, Augusta-Kranken-Anstalt gGmbH, Bochum 44791, Germany; juris.meier{at}rub.de

https://doi.org/10.1136/gutjnl-2023-331213

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    With interest we have read the recent article by Liu et al.1 We would like to raise a few concerns that we believe warrant further discussion. Thus, given the retrospective nature of the study, significant confounders may have exerted a substantial influence on the actual results. These confounding variables cannot be adequately addressed through propensity score matching. In this regard, duration of diabetes (which has not been reported in the study) is a crucial factor to consider, as longer diabetes duration may be linked to a higher prevalence of diabetic gastroparesis. Notably, gastroparesis is often underdiagnosed in patients with diabetes, since clinical symptoms are typically rare even in patients with marked abnormalities in gastric emptying.2 Therefore, uneven distribution of subjects with gastroparesis in the study cohorts is possible. Furthermore, the study did not match subjects based on the use of proton pump inhibitors. Also, the analysis did …

    View Full Text

    Footnotes

    • DRQ and JJM contributed equally.

    • Contributors DRQ and JJM contributed equally.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests DRQ has received a research award sponsored by Sanofi; has received honoraria for lectures, presentations, and educational events by Eli Lilly & Co. and Novo Nordisk; has received support for attending meetings and/or travel from Eli Lilly & Co. and Cook Medical. JJM has received lecture honoraria and consulting fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme (MSD), Novo Nordisk, Novartis and Sanofi; has received reimbursement of congress participation fees and travel expenses from MSD, Novo Nordisk, and Sanofi; and has initiated projects supported by Boehringer-Ingelheim, MSD, Novo Nordisk and Sanofi.

    • Provenance and peer review Not commissioned; externally peer reviewed.